A large survey of over 4,000 Moroccan students found that female students were more opposed to both medical and recreational cannabis legalization, while tobacco users, cannabis users, and those reporting depression were more supportive of medical cannabis laws. This is the first study to examine youth attitudes in Morocco following the country’s landmark 2021 cannabis reform, though the cross-sectional design cannot establish whether attitudes drive behavior or the reverse.

Morocco’s 2021 Law No. 13-21 represented a dramatic policy pivot for Africa’s largest cannabis resin producer, legalizing medical and industrial cannabis in a country where cannabis culture has deep historical roots but legal access was previously prohibited. How young people perceive this legislation matters enormously for public health planning, harm reduction messaging, and clinical counseling in a population at elevated risk of cannabis-related harms. Until now, no published research had examined Moroccan youth attitudes in the post-reform era, leaving a critical gap in understanding who is receptive to medical cannabis frameworks and who resists them.

Morocco occupies a unique position in global cannabis regulation. As the world’s leading producer of cannabis resin and a country where informal cannabis markets have long operated in the northern Rif region, the passage of Law No. 13-21 in 2021 created a new legal framework permitting medical and industrial cannabis use. This study sought to fill a gap in post-legislation research by surveying how young Moroccans, a demographically important and potentially vulnerable population, perceive these changes. The investigators designed a quantitative, cross-sectional survey administered to 4,040 high school and university students in southern Morocco, collecting data on demographic characteristics, substance use behaviors (tobacco and cannabis), self-reported depression, awareness of the new law, and attitudes toward both medical cannabis use and recreational cannabis use.

The central findings showed that female students were significantly more likely than males to oppose both medical and recreational cannabis legalization, and were also more likely to believe that legalization would discourage users from seeking abstinence. Conversely, tobacco smokers, current cannabis users, and students who reported depression expressed more favorable attitudes toward medical cannabis legislation. These associations are consistent with international patterns of sex-differentiated drug policy attitudes but must be interpreted cautiously. The cross-sectional design makes it impossible to determine whether attitudes preceded substance use or mental health status, or the reverse. The authors acknowledge the need for longitudinal research and note that their findings are limited to one region of Morocco and to students enrolled in educational institutions. Detailed effect sizes and regression parameters were not available in the extracted text.

This study does what a first-pass attitudinal survey should do: it establishes that attitudes toward cannabis legislation among Moroccan youth are not monolithic, and that sex, personal experience with substances, and mental health status all play a role in shaping those views. That is useful groundwork. But the chasm between associational survey data and actionable clinical insight is wide. We cannot tell from this design whether students with depression are drawn to support medical cannabis because they perceive it as therapeutic, or whether some unmeasured third variable drives both depression and favorable attitudes. The absence of validated depression screening details and the regional restriction to southern Morocco make generalization risky.

In my own practice, I see something broadly similar: patients who have already used cannabis or who have chronic conditions tend to be more open to medical cannabis discussions, while those without personal experience are often more skeptical. What I take from this Moroccan data is a reminder that public health messaging around new cannabis laws must be calibrated to audience. A one-size-fits-all information campaign will not reach young women the same way it reaches young men, nor will it resonate equally with those who already use substances.

This study sits at the earliest stage of the research arc for a newly regulated cannabis environment. It provides a descriptive baseline, not a foundation for clinical recommendations. The research community studying cannabis attitudes globally has consistently found that personal experience with cannabis, male sex, and more liberal political orientation predict favorable attitudes toward legalization; this Moroccan survey largely confirms those patterns within a distinct cultural and regulatory context. What it adds is the finding that depression status may be independently associated with pro-medical cannabis attitudes in a North African student population, a relationship that warrants further investigation with validated psychiatric instruments and longitudinal follow-up.

For clinicians practicing in regions with evolving cannabis legislation, the practical takeaway is not pharmacological but communicative. Patients’ attitudes toward medical cannabis are likely influenced by sex, personal substance use history, and mental health status, all of which are relevant to the clinical encounter. When discussing cannabis therapeutics with a young patient who reports depression, clinicians should be prepared for a higher baseline of receptivity but also for the possibility that this receptivity reflects self-medication patterns rather than informed preference. The single most actionable recommendation from this research: tailor educational conversations about cannabis to the demographic and experiential profile of the patient in front of you, rather than relying on generic risk-benefit messaging.